Jump to content
  • Posts

    • Related ArticlesPublication of national dermatology guidelines as a Research Letter in the BJD: can less ever be enough? Br J Dermatol. 2020 06;182(6):1319-1320 Authors: van Zuuren EJ, Arents BWM, Flohr C, Ingram JR PMID: 32476154 [PubMed - indexed for MEDLINE] {url} = URL to article
    • Holistic care of patients with rosacea. J Cosmet Dermatol. 2020 Oct 14;: Authors: Searle T, Al-Niaimi F, Ali FR Abstract We thank the authors for their commentary on our article Rosacea and the Cardiovascular System.1 The authors discuss the risk of "excessive health examination". Whilst we do not advocate over investigation or over treatment of any patient, the association between cardiovascular disease and rosacea is evident2,3 and any dermatologist or clinician treating patients with rosacea should be aware of these associations as well as other extracutaneous associations of rosacea. PMID: 33051962 [PubMed - as supplied by publisher] {url} = URL to article
    • Acne in the first three decades of life: An update of a disorder with profound implications for all decades of life. Dis Mon. 2020 Oct 08;:101103 Authors: Greydanus DE, Azmeh R, Cabral MD, Dickson CA, Patel DR Abstract Acne vulgaris is a chronic, inflammatory, skin condition that involves the pilosebaceous follicles and is influenced by a variety of factors including genetics, androgen-stimulation of sebaceous glands with abnormal keratinization, colonization with Cutibacterium acnes (previously called Propionibacterium acnes), and pathological immune response to inflammation. Acne can occur at all ages and this discussion focuses on the first three decades of life. Conditions that are part of the differential diagnosis and/or are co-morbid with acne vulgaris are also considered. Acne in the first year of life includes neonatal acne (acne neonatorum) that presents in the first four weeks of life and infantile acne that usually presents between 3 and 6 months of the first year of life with a range of 3 to 16 months after birth. Acne rosacea is a chronic, inflammatory, skin condition that is distinct from acne vulgaris, typically presents in adults, and has four main types: erythemato-telangiectatic, papulopustular, phymatous and ocular. Treatment options for acne vulgaris include topical retinoids, topical benzoyl peroxide, antibiotics (topical, oral), oral contraceptive pills, isotretinoin, and others. Management must consider the increasing impact of antibiotic resistance in the 21st century. Psychological impact of acne can be quite severe and treatment of acne includes awareness of the potential emotional toll this disease may bring to the person with acne as well as assiduous attention to known side effects of various anti-acne medications (topical and systemic). Efforts should be directed at preventing acne-caused scars and depigmentation on the skin as well as emotional scars within the person suffering from acne. PMID: 33041056 [PubMed - as supplied by publisher] {url} = URL to article
    • Brazilian Society of Dermatology consensus on the use of oral isotretinoin in dermatology. An Bras Dermatol. 2020 Oct 03;: Authors: Bagatin E, Costa CS, Rocha MADD, Picosse FR, Kamamoto CSL, Pirmez R, Ianhez M, Miot HA Abstract BACKGROUND: Isotretinoin is a synthetic retinoid, derived from vitamin A, with multiple mechanisms of action and highly effective in the treatment of acne, despite common adverse events, manageable and dose-dependent. Dose-independent teratogenicity is the most serious. Therefore, off-label prescriptions require strict criteria. OBJECTIVE: To communicate the experience and recommendation of Brazilian dermatologists on oral use of the drug in dermatology. METHODS: Eight experts from five universities were appointed by the Brazilian Society of Dermatology to develop a consensus on indications for this drug. Through the adapted DELPHI methodology, relevant elements were listed and an extensive analysis of the literature was carried out. The consensus was defined with the approval of at least 70% of the experts. RESULTS: With 100% approval from the authors, there was no doubt about the efficacy of oral isotretinoin in the treatment of acne, including as an adjunct in the correction of scars. Common and manageable common adverse events are mucocutaneous in nature. Others, such as growth retardation, abnormal healing, depression, and inflammatory bowel disease have been thoroughly investigated, and there is no evidence of a causal association; they are rare, individual, and should not contraindicate the use of the drug. Regarding unapproved indications, it may represent an option in cases of refractory rosacea, severe seborrheic dermatitis, stabilization of field cancerization with advanced photoaging and, although incipient, frontal fibrosing alopecia. For keratinization disorders, acitretin performs better. In the opinion of the authors, indications for purely esthetic purposes or oil control are not recommended, particularly for women of childbearing age. CONCLUSIONS: Approved and non-approved indications, efficacy and adverse effects of oral isotretinoin in dermatology were presented and critically evaluated. PMID: 33036809 [PubMed - as supplied by publisher] {url} = URL to article
    • This is a note from the RRDi Treasurer about grant writing basics. Please read this page first! The RRDi received some education grants from Galderma which you can review here:  https://irosacea.org/articles/rrdi-education-grants/ Grant writing is a tedious and arduous task and we appreciate your volunteering to help us.  We went through all sorts of hoops with Galderma to get those grants. Now the process has changed and we are still trying to figure it out. What each company requires is different and you have to go through hoops to learn.  Basically, it would be prudent to try to learn how to apply for grants from pharmaceutical companies that make rosacea treatments. You can learn what prescription treatments for rosacea are here:  https://irosacea.org/forums/forum/21-prescription-treatments/ Some of the major pharmaceutical companies that make rosacea treatments are:  Galderma, Allergan, Alma, Almirall, Bayer, BioPharmX, Bristol Meyers, Candela, Chicet, Clinique, Cutanea, EPI Health, Foamix, GSK, Havione, Johnson & Johnson, Roche, Pfizer, Salix, Sanofi, Sol-Gel  Contacting these pharmaceutical companies and asking them what the hoops are to go through to obtain grants is what you should do. We have Medical Advisory Consultants who might answer some questions about rosacea if you need to know anything. The list is found here:  https://irosacea.org/mac/ Go through Apurva Tathe with your questions first since she has access to contacting the RRDi MAC members above in the list if you have medical rosacea research questions.   There are, of course, foundations that offer money for grants and each foundation has its hoops to go through, i.e., Bill and Melinda Gates Foundation https://www.gatesfoundation.org And there are many others. You can google 'how to apply for grants' which will give you more results.  When filling out forms use the following:  Address:  Rosacea Research & Development Institute  PO Box 858 Centre, AL 35960 EIN 20-1259275
  • Create New...